Novo Nordisk CEO Mike Doustdar recently appeared on CNBC to defend his company's decision to sue rival Eli Lilly. The lawsuit centers on advertising claims regarding weight-loss treatments. Doustdar stated that while he welcomes aggressive market competition, he maintains that information provided to consumers and physicians must be accurate and complete.
At the heart of the dispute is how Eli Lilly promotes its drug Zepbound. Novo Nordisk alleges that these advertisements mislead the public by comparing results from their high-dose medication against older, lower-dose versions of Novo’s Wegovy. Novo Nordisk points to clinical data showing their own updated high-dose version offers weight-loss results comparable to those marketed by Eli Lilly.
Doustdar argued that patients deserve the full picture when choosing their treatment options. He asserted that relying on legacy data creates an incomplete comparison that does not reflect the current reality of the market. Novo Nordisk contends that consumers should understand the profile of all available products before making health decisions.
Eli Lilly has responded by standing behind its advertising. The company noted that their claims are supported by head-to-head clinical trial data and has questioned the equivalence of the newer Wegovy high-dose formulation. Lilly emphasized that they continue to focus on their market presence and the efficacy of their own weight-loss solutions.
This legal friction highlights the intense struggle for market share in the booming GLP-1 sector. With both companies launching new pills and injection options, investors and patients remain focused on how these firms manage their clinical messaging and commercial growth in an increasingly crowded space.